Zanamivir: from drug design to the clinic.

Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child. Emerg Infect Dis (2011) 0.94

Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats. Biomol Ther (Seoul) (2013) 0.75

Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (1993) 8.62

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med (2000) 5.98

Resistance of influenza viruses to neuraminidase inhibitors--a review. Antiviral Res (2000) 3.68

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis (1998) 3.47

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med (1989) 3.16

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA (1999) 2.98

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother (1993) 2.92

Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother (1983) 2.53

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA (1996) 2.30

Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol (1996) 2.26

Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother (1994) 2.22

Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother (1981) 1.99

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis (1999) 1.87

Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis (1989) 1.73

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials. Arch Intern Med (2001) 1.68

The impact and cost of influenza in the elderly. Arch Intern Med (1993) 1.65

Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother (1999) 1.58

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet (1999) 1.54

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect (2000) 1.48

Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position. Glycoconj J (1993) 1.29

GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother (1995) 1.24

Zanamivir: a review of clinical safety. Drug Saf (1999) 1.20

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J (2000) 1.16

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother (2000) 1.11

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet (1999) 1.04

Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res (1994) 1.00

Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin Pharmacokinet (1999) 0.99

Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. GG167 Group. Antivir Ther (1999) 0.99

Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Respir Med (2000) 0.88

Influenza, influenza vaccine, and amantadine/rimantadine. J Fam Pract (1997) 0.87

The low potential for drug interactions with zanamivir. Clin Pharmacokinet (1999) 0.84

Preclinical development of low toxicity drugs: focus on zanamivir, an anti-influenza drug. Drug Saf (1998) 0.81